Cardiovascular and cerebrovascular outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension.

[1]  Deepak L. Bhatt,et al.  Non-adherence to cardiovascular medications. , 2014, European heart journal.

[2]  S. Yusuf,et al.  Impact of telmisartan on cardiovascular outcome in hypertensive patients at high risk: a Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease subanalysis , 2014, Journal of hypertension.

[3]  J. Chalmers.  Are the effects of telmisartan more marked in hypertensive patients? , 2014, Journal of hypertension.

[4]  A. Dominiczak,et al.  2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. , 2013, Journal of hypertension.

[5]  M. Silvestrini,et al.  Elevated Blood Pressure in the Acute Phase of Stroke and the Role of Angiotensin Receptor Blockers , 2013, International journal of hypertension.

[6]  L. Ruilope,et al.  Prevention of microalbuminuria in patients with type 2 diabetes and hypertension , 2012, Journal of hypertension.

[7]  N. Campbell.  2011 Canadian Hypertension Education Program recommendations: an annual update. , 2011, Canadian family physician Medecin de famille canadien.

[8]  K. Arakawa,et al.  Antihypertensive Efficacy of Olmesartan Medoxomil and Candesartan Cilexetil in Achieving 24-Hour Blood Pressure Reductions and Ambulatory Blood Pressure Goals , 2011, Clinical drug investigation.

[9]  S. Bangalore,et al.  Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials , 2011, BMJ : British Medical Journal.

[10]  D. Su,et al.  A Systematic Review of Angiotensin Receptor Blockers in Preventing Stroke , 2009, Stroke.

[11]  A. Hall,et al.  Angiotensin receptor blockers should be regarded as first-line drugs for stroke prevention in both primary and secondary prevention settings: no. , 2009, Stroke.

[12]  J. Ioannidis,et al.  The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration , 2009, BMJ : British Medical Journal.

[13]  A. Sierra.  Main results and clinical interpretations from the TRANSCEND study. , 2009 .

[14]  M. Law,et al.  Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.

[15]  G. Mancia,et al.  Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials , 2009, Journal of hypertension.

[16]  D. Altman,et al.  Assessing Risk of Bias in Included Studies , 2008 .

[17]  D. Altman,et al.  Chapter 8: Assessing risk of bias in included studies , 2008 .

[18]  I. McKeith,et al.  Candesartan and cognitive decline in older patients with hypertension , 2008, Neurology.

[19]  Julio Sánchez-Meca,et al.  Confidence intervals for the overall effect size in random-effects meta-analysis. , 2008, Psychological methods.

[20]  J. Molnar,et al.  Prevention of Atrial Fibrillation by Way of Abrogation of the Renin-Angiotensin System: A Systematic Review and Meta-Analysis , 2008, American journal of therapeutics.

[21]  A. Bomback,et al.  The incidence and implications of aldosterone breakthrough , 2007, Nature Clinical Practice Nephrology.

[22]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[23]  Richard Lewanczuk,et al.  More medications, fewer pills: combination medications for the treatment of hypertension. , 2007, The Canadian journal of cardiology.

[24]  S. Oparil,et al.  Comparison of Increasing Doses of Olmesartan Medoxomil, Losartan Potassium, and Valsartan in Patients With Essential Hypertension , 2007, Journal of clinical hypertension.

[25]  A. Garg,et al.  Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation. , 2007, Journal of clinical epidemiology.

[26]  G. Skrepnek,et al.  Persistence, Adherence, and Risk of Discontinuation Associated with Commonly Prescribed Antihypertensive Drug Monotherapies , 2007, The Journal of the American Board of Family Medicine.

[27]  A. Hall,et al.  Angiotensin Receptor Blockers May Increase Risk of Myocardial Infarction: Unraveling the ARB-MI Paradox , 2006, Circulation.

[28]  R. Tsuyuki,et al.  Response to Tsuyuki and McDonald , 2006 .

[29]  P. Trenkwalder.  The Study on COgnition and Prognosis in the Elderly (SCOPE) – recent analyses , 2006, Journal of hypertension. Supplement : official journal of the International Society of Hypertension.

[30]  R. Fagard,et al.  Apparent effect on blood pressure is only partly responsible for the risk reduction due to antihypertensive treatments , 2005, Fundamental & clinical pharmacology.

[31]  J. O’Keefe,et al.  Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. , 2005, Journal of the American College of Cardiology.

[32]  T. Unger,et al.  The AT2 receptor—A matter of love and hate , 2005, Peptides.

[33]  I. Lauder,et al.  Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension , 2005, Journal of Human Hypertension.

[34]  A. Hofman,et al.  The Study on COgnition and Prognosis in the Elderly (SCOPE) – Major CV events and stroke in subgroups of patients , 2005, Blood pressure.

[35]  S. Sheu,et al.  A double‐blind comparison of the efficacy and tolerability of telmisartan 40–80 mg vs. losartan 50–100 mg in Taiwanese hypertensive patients , 2004, International journal of clinical practice. Supplement.

[36]  P. Boyle,et al.  Beyond classical meta-analysis: can inadequately reported studies be included? , 2004, Drug discovery today.

[37]  K. Asayama,et al.  Control of blood pressure as measured at home and office, and comparison with physicians' assessment of control among treated hypertensive patients in Japan: First Report of the Japan Home versus Office Blood Pressure Measurement Evaluation (J-HOME) study. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[38]  A. Hofman,et al.  Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). , 2004, Journal of the American College of Cardiology.

[39]  T. Unger,et al.  Are angiotensin receptor blockers neuroprotective? , 2004, Current hypertension reports.

[40]  R. Fogari,et al.  Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. , 2004, Hypertension research : official journal of the Japanese Society of Hypertension.

[41]  L. Ruilope,et al.  Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension , 2004, Journal of hypertension.

[42]  B. Lévy.  Can Angiotensin II Type 2 Receptors Have Deleterious Effects in Cardiovascular Disease?: Implications for Therapeutic Blockade of the Renin–Angiotensin System , 2003, Circulation.

[43]  Karl Swedberg,et al.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. , 2003, The New England journal of medicine.

[44]  M. Law,et al.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. , 2003, Health technology assessment.

[45]  B. Becker,et al.  How meta-analysis increases statistical power. , 2003, Psychological methods.

[46]  A. Hofman,et al.  The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial , 2003, Journal of hypertension.

[47]  K. Dickstein,et al.  Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial , 2002, The Lancet.

[48]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[49]  E. Lewis,et al.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.

[50]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[51]  R. Carey,et al.  Angiotensin-Converting Enzyme Inhibition Potentiates Angiotensin II Type 1 Receptor Effects on Renal Bradykinin and cGMP , 2001, Hypertension.

[52]  M. Burnier,et al.  Angiotensin II Type 1 Receptor Blockers , 2001, Circulation.

[53]  P. Conlin.  Angiotensin II Antagonists in the Treatment of Hypertension: More Similarities Than Differences. , 2000, Journal of clinical hypertension.

[54]  Bertram Pitt,et al.  Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial—the Losartan Heart Failure Survival Study ELITE II , 2000, The Lancet.

[55]  S. Oparil,et al.  Essential hypertension. Part I: definition and etiology. , 2000, Circulation.

[56]  G. Smith,et al.  Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.

[57]  P. Timmermans,et al.  Discovery of losartan, the first angiotensin II receptor antagonist. , 1995, Journal of human hypertension.

[58]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[59]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[60]  David H. G. Smith.  Comparison of Angiotensin II Type 1 Receptor Antagonists in the Treatment of Essential Hypertension , 2012, Drugs.

[61]  L. Thalib,et al.  Cardiovascular Outcomes in High-Risk Patients without Heart Failure Treated with ARBs , 2009 .

[62]  J. Terasaki,et al.  A renoprotective effect of low dose losartan in patients with type 2 diabetes. , 2008, Diabetes research and clinical practice.

[63]  Marco Ranucci,et al.  A Meta-analysis of Randomized Clinical Trials , 2008 .

[64]  Andrea Cipriani,et al.  Imputing missing standard deviations in meta-analyses can provide accurate results. , 2006, Journal of clinical epidemiology.